We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Life Sciences

  • March 21, 2019

    Vt. Can Move Ahead With Opioid Suit Against Purdue Pharma

    Vermont’s attorney general’s office announced Thursday that it will continue its lawsuit against Purdue Pharma for the company’s alleged role in fueling opioid addiction in the Green Mountain State, after a state judge ruled against the OxyContin maker’s bid to kill the case.

  • March 21, 2019

    Swiss Firm Takes French Biotech Co. Private For €730.1M

    Ares Life Sciences said Thursday it will snap up the rest of French allergy pharmaceutical company Stallergenes Greer it doesn’t already own in a 730.1 million euro ($832.5 million) deal guided by Skadden and Clifford Chance.

  • March 21, 2019

    Omnicare's $20M Settlement With Investors Gets Initial OK

    A Kentucky federal court granted preliminary approval on Thursday to a settlement in which Omnicare Inc. agreed to pay $20 million to resolve a 13-year-old securities suit that at one point made its way to the U.S. Supreme Court.

  • March 21, 2019

    17 Alleged Misstatements Cut From Dr. Reddy’s Investor Suit

    A New Jersey federal judge told a pension fund on Wednesday that it only has standing to pursue securities claims against Dr. Reddy's for five alleged misstatements it made immediately prior to the fund's purchase of the pharmaceutical company's stock.

  • March 21, 2019

    What To Know About New FDA Commissioner Sharpless

    Career scientist and physician Dr. Norman Sharpless will leave his post as the head of the National Cancer Institute to take over the U.S. Food and Drug Administration when Scott Gottlieb steps down in April. Here’s what you should know about the new interim commissioner.

  • March 21, 2019

    Sens. Seek Answers About Doctor-Owned Medical Suppliers

    Sens. Chuck Grassley, R-Iowa, and Ron Wyden, D-Ore., have sent a letter to agencies within the U.S. Department of Health and Human Services seeking answers on their efforts to monitor medical suppliers that are partly owned by the physicians whose practices they supply. 

  • March 21, 2019

    1st Circ. Loss Dooms New Asacol Buyer Class, Allergan Says

    Allergan PLC said a group that claims the company's anti-competitive methods caused it to overpay for its ulcerative colitis drug should not get a second chance at class certification after the First Circuit knocked down its first attempt.

  • March 21, 2019

    Rejected J&J Job Seeker Must Arbitrate Claim, 3rd Circ. Told

    A Johnson & Johnson unit on Thursday urged the Third Circuit to toss a would-be employee's proposed class claims that he was unfairly denied a job due to an erroneous criminal background check, arguing that his agreement to arbitrate claims with a temporary employment staffing agency extended to the pharmaceutical company.

  • March 21, 2019

    Firms Contest Class Counsel Bid In Trevena Investor Suit

    Citing alleged misstatements made by an investor represented by rival attorneys, Block & Leviton LLP and Kaufman Coren & Ress LLP have urged a Pennsylvania federal judge to name them class counsel in litigation accusing Trevena Inc. of artificially inflating its share value.

  • March 21, 2019

    Law360's Life Sciences Editorial Advisory Board

    Law360 is pleased to announce the formation of its 2019 Life Sciences Editorial Advisory Board.

  • March 20, 2019

    Health Care IP Key To Cutting Costs: FTC Member

    Enforcing intellectual property rights in health care and ensuring competition to everyone’s benefit — especially finding ways to control skyrocketing prescription drug costs — has emerged as a priority at the Federal Trade Commission, a Republican member of the body said Wednesday.

  • March 20, 2019

    What’s In A Judgeship? More Than Meets The Eye

    Figuring out what constitutes a manageable workload for the nation’s district judges is no simple task. Getting the judiciary the resources it needs is even harder.

  • March 20, 2019

    Swamped: How Magistrate Judges Salvaged Louisiana's Judicial Crisis

    The Western District of Louisiana is supposed to have seven district judges. But for a year, most of the courthouses were operating without a single Article III judge. As usual, magistrate judges picked up the slack.

  • March 20, 2019

    Full Fed. Circ. Won't Review Stryker's $254M Damages Win

    The full Federal Circuit shot down Zimmer Inc.’s request to re-evaluate the $254 million bill it's facing for infringing Stryker Corp.’s surgical tool patents in a case that led the U.S. Supreme Court to relax the standard for awarding enhanced damages.

  • March 20, 2019

    Pointed Questions Suggest Longer FCA Time Limit Is Likely

    An extended time limit for False Claims Act cases where the government doesn't intervene, seemingly supported by the justices at arguments for a pending U.S. Supreme Court case, marks a significant potential expansion of already-high FCA-related risks and costs for federal contractors, attorneys said.

  • March 20, 2019

    Teva's 'Strategic Decision' On FCA Testimony Gets Judge's Ire

    A New York federal judge said that Teva Pharmaceuticals made a "strategic decision" not to challenge expert testimony in a False Claims Act case and that she has "no interest" in revisiting a recent ruling in light of new challenges.

  • March 20, 2019

    J&J Talc Supplier's Ex-Owners Ask For Ch. 11 Shield

    The former owners of bankrupt Johnson & Johnson talc supplier Imerys Talc America Inc. asked a Delaware bankruptcy judge Wednesday to extend to them the protections of the automatic stay granted to the debtor in Chapter 11 cases so a dispute over insurance policy proceeds can be resolved.

  • March 20, 2019

    Monsanto Jury Told $63B Co. Should Pay Up Over Roundup

    Monsanto should pay a California man for failing to warn about its weedkiller Roundup's cancer risks, his attorney told a federal jury during opening statements in the trial's second phase, declining to put a number on punitive damages but noting that Bayer recently acquired Monsanto for $63 billion.

  • March 20, 2019

    Workers Can Sue Labs For Shoddy Drug Tests: SC Justices

    Laboratories that conduct drug tests for employers have a legal duty to the workers they test to perform them accurately, the South Carolina Supreme Court held Wednesday, saying a former BMW employee who was fired for failing a drug screening can sue the lab that tested him over a purported false positive.

  • March 20, 2019

    Dental Supply Co. Must Face Price-Fixing Suit, Investors Say

    A proposed class of Patterson Cos. Inc. investors has asked a Minnesota federal judge not to toss their suit accusing the dental supply company of working with competitors to fix dental supply prices, saying a Federal Trade Commission investigation gave them enough evidence to back up the case's claims.

Expert Analysis

  • Lenders Score Major High Court Victory In Foreclosure Case

    Author Photo

    The U.S. Supreme Court's unanimous ruling on Wednesday in Obduskey v. McCarthy & Holthus LLP removes nearly all activities taken by creditors seeking nonjudicial foreclosure of liens and mortgages from the ambit of the Fair Debt Collection Practices Act, says John Baxter of Nelson Mullins Riley & Scarborough LLP.

  • Trial Counsel's Role On A Mass Tort Virtual Law Team

    Author Photo

    Trial counsel’s contribution to the virtual law team throughout the life cycle of a mass tort litigation rests in the key skill of viewing the case through the eyes of the ultimate audience for the defense, the jury, say attorneys at Covington & Burling LLP and Faegre Baker Daniels LLP.

  • Tech Trends From SXSW Pose Unique Questions For Lawyers

    Author Photo

    These days, a popular theme in media is that lawyers' jobs will be taken by robots. However, based on the tech issues discussed at the South by Southwest technology conference in Austin, Texas, last month, robots may in fact need lawyers, says Nick Abrahams of Norton Rose Fulbright.

  • In Bar Admissions Process, It's Candor Or Bust

    Author Photo

    You passed the bar exam and are ready for the character and fitness committee interview. Time to think about how to discuss that minor incident in college, that misdemeanor in high school or that mental health issue that you have totally under control, says Richard Maltz of Frankfurt Kurnit Klein & Selz PC.

  • Off-Label Promotion Still A Litigation Risk For Pharma Cos.

    Author Photo

    In recent years, the U.S. Department of Justice has shown some reluctance to bring cases involving off-label promotion of pharmaceutical products, but this type of marketing remains the driving force behind many product liability and mass tort litigations, say Dae Lee and Jesse Dresser of Frier Levitt LLC.

  • Justices Offer Practical Approach To Class Appeal Deadline

    Author Photo

    The U.S. Supreme Court's recent opinion in Nutraceutical v. Lambert held that Federal Rule of Civil Procedure 23(f)’s 14-day limit for class certification appeals is not subject to equitable tolling, presenting important lessons for both the winners and losers of class certification orders, say attorneys at Faegre Baker Daniels.

  • Series

    Judging A Book: Bashant Reviews 'Doing Justice'

    Author Photo

    My initial reaction to "Doing Justice" was that author Preet Bharara may have bitten off more than he could chew — an accusation leveled against him when he served as U.S. attorney for the Southern District of New York — but I found the book full of helpful gems, says U.S. District Judge Cynthia Bashant of the Southern District of California.

  • If There, Then Here: How Gov't Probes Help Antitrust Plaintiffs

    Author Photo

    Private plaintiffs seeking to bolster their price-fixing complaints by citing government investigations or guilty pleas concerning different markets should consider instructive decisions from the Auto Parts, Generic Drugs, and SRAM and Flash Memory litigations, say William Reiss and Dave Rochelson of Robins Kaplan LLP.

  • Firms Can Leverage Communications When Economy Is Slow

    Author Photo

    Though most experts believe that an imminent recession is unlikely, slowdown fears are increasing. Now is the time for firms to consider how to best leverage their communications and marketing teams to lessen impacts from a potential economic slowdown, says Tom Orewyler of Tom Orewyler Communications LLC.

  • Opinion

    Hikma V. Vanda Exaggerates Treatments' Patent Eligibility

    Author Photo

    Hikma's recent certiorari petition claims the Federal Circuit’s decision in Vanda v. West-Ward amounts to a free pass under Section 101 for method-of-treatment claims. But Vanda is a fact-specific ruling that attempts to find some middle ground in the U.S. Supreme Court’s Section 101 precedents, say Sasha Rao and Erin Gaddes of Maynard Cooper & Gale PC.